<DOC>
	<DOCNO>NCT00000962</DOCNO>
	<brief_summary>To assess safety tolerance multiple oral dos Nevirapine ( BI-RG-587 ) . To generate data pharmacokinetics dose proportionality Nevirapine multiple dose . To characterize pattern virological activity vivo . Improvement virological end point examine association dose absorption . To determine whether development resistance reflect return virological activity , , marker reflect resistance . To determine improvement immunological endpoint detectable number patient study . A compound free toxic effect nucleoside chain terminator zidovudine ( AZT ) may advantage currently available treatment HIV infection . Such compound advantage active AZT-resistant isolates . Nevirapine ( BI-RG-587 ) show vitro inhibitory activity HIV-1 reverse transcriptase ( RT ) . The molecular mechanism RT inhibitory effect hypothesize non-competitive inhibition due bind RT site distinct RNA template primer , deoxynucleotide triphosphate RNase H catalytic site .</brief_summary>
	<brief_title>The Safety Effectiveness BI-RG-587 HIV-Infected Patients</brief_title>
	<detailed_description>A compound free toxic effect nucleoside chain terminator zidovudine ( AZT ) may advantage currently available treatment HIV infection . Such compound advantage active AZT-resistant isolates . Nevirapine ( BI-RG-587 ) show vitro inhibitory activity HIV-1 reverse transcriptase ( RT ) . The molecular mechanism RT inhibitory effect hypothesize non-competitive inhibition due bind RT site distinct RNA template primer , deoxynucleotide triphosphate RNase H catalytic site . This stagger dose escalation cohort trial examines safety , tolerance , pharmacokinetics activity Nevirapine ( BI-RG-587 ) patient HIV infection . Groups 10 patient must complete 4 week therapy without require dose interruption next dosage level initiate . All 10 patient must enrol low dosage level next dosage level initiate . Patients discontinue antiretroviral therapy , sign informed consent , 28 day prior receipt first dose Nevirapine . Screening lab test , include p24 antigen plasma viremia , CD4+ cell count determination perform 21 day prior drug dose Part I . Patients notify screen laboratory measure exclude study participation . Upon notification patient option resume prior antiretroviral therapy repeat value one week . Part II consist two 8-hour intensive blood sample period plus frequent trough value blood sampling . Safety , trough value blood sampling , activity assessment perform Part III . An assessment dose-tolerance activity make Study Week 12 order patient may continue Nevirapine chronic therapy additional 12 week . The Final Visit Part IV take place Study Week 24 complete trial . Patients complete 24 week offer option continue Nevirapine chronic therapy initial alter dose separate open-label protocol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Pentamidine dapsone prophylaxis Pneumocystis carinii pneumonia ( PCP ) patient CD4+ cell count = &lt; 200 cells/mm3 . Antifungal prophylaxis oral fluconazole ketoconazole . Antiviral prophylaxis maximum 1 gram oral acyclovir per day . Acute therapy intercurrent infection long therapy exclude medication exclude opportunistic infection . Patients must : Positive HIV antibody test result ELISA . Average CD4+ cell count 60 21 day prior study begin = &lt; 400 cells/mm3 . Seven 10 patient treatment arm must p24 antigen level = &gt; 70 pg/ml ( &gt; 50 pg/ml U. Mass . site ) plasma viremic . Preserved hematologic , hepatic , renal function define require lab value . Ambulatory performance score = &gt; 70 Karnofsky . Ability voluntarily provide write informed consent prior treatment . Willingness ability follow protocol requirement . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active cytomegalovirus disease . Toxoplasmic encephalitis require suppressive therapy . Mycobacteriosis require maintenance chemotherapy . Visceral Kaposi 's sarcoma require chemotherapy and/or irradiation . Malignancy Kaposi 's sarcoma limit cutaneous basal cell carcinoma . More mild diarrhea ( defined transient &gt; 4 loose stool per day ) . Concurrent Medication : The following medication / substance may NOT ingested one hour 4 hour Nevirapine dose : Antacids ( particularly contain calcium carbonate ) . Cimetidine . Carafate . Cholestyramine resin . Alcohol alcoholcontaining substance . Benzodiazepines ( diazepam , triazolam ) . Excluded : Any approve investigational antiretroviral , immunosuppressive , cytotoxic drug . Glucocorticoids steroid hormone ( include oral contraceptive ) . Dicumarol , warfarin , anticoagulant medication . Nitroglycerin . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol . Isoniazid . Any sulfonamide medication . Patients follow excluded : History clinically important disease HIV infection define investigator possibly put patient risk study participation . Conditions list Exclusion CoExisting Conditions symptom . Having receive approved investigational antiretroviral , immunosuppressive , cytotoxic drug experimental drug 4 week study entry . A positive zidovudine ( AZT ) detection assay perform 7 day prior drug dose exclude patient study participation . Prior Medication : Excluded within 4 week study entry : Any approve investigational antiretroviral , immunosuppressive cytotoxic drug . Glucocorticoids steroid hormone ( include oral contraceptive ) . Dicumarol , warfarin , anticoagulant drug . Nitroglycerin . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol . Isoniazid . Antiepileptics ( phenobarbital barbiturate ) . Trimethoprim / sulfamethoxazole ( Bactrim ) . Risk Behavior : Excluded : Patients whose use alcohol drug sufficient impair compliance protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1994</verification_date>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Nevirapine</keyword>
</DOC>